Nanogen releases enterovirus reagent employing newly patented hybridization technology.
"According to the Centers for Disease Control, enteroviruses cause an estimated 10 to 15 million symptomatic cases a year in the United States," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Enterovirus testing constitutes a segment of the infectious disease molecular diagnostics market, which is expected to reach $2.3 billion by 2010."
"Detection of viral infections by real-time PCR is typically faster, more sensitive and more specific than through other methods," said Birndorf, "and should help reduce the healthcare costs associated with enteroviral infections." Aseptic meningitis cases account for tens of thousands of hospitalizations every year.
George E. Buck, chief of microbiology at Norton Healthcare in Louisville, KY, finds the MGB Alert ENV product to be "very sensitive and easy to use. Physicians at our hospital rely on our results to help them diagnose these infections."
Nanogen's MGB Alert Enterovirus analyte specific reagent (ASR), like all MGB Alert products, utilizes novel detection chemistry claimed in United States Patent 7,045,610, issued to Nanogen May 16. The '610 patent, "Modified Oligonucleotides for Mismatch Discrimination," claims the use of modified bases to improved hybridization-based diagnostic assays.
The patented chemistry is employed in most of the company's ASRs and research products, enabling laboratories to develop multiple assays with universal parameters, which increases the efficiency and throughput of clinical testing. The super bases (Super A, Super T, Super G and Super N) and MGB technology described in '610 allow the use of shorter probes with increased sensitivity to mismatches, which have proved essential for detecting short conserved sequences of enteroviruses as well as other pathogens.
"Specifically, '610 allows Nanogen to deliver real-time PCR probe and primer designs for targets that would be otherwise intractable," said Birndorf.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
|Printer friendly Cite/link Email Feedback|
|Comment:||Nanogen releases enterovirus reagent employing newly patented hybridization technology.|
|Publication:||BIOTECH Patent News|
|Date:||Jul 1, 2006|
|Previous Article:||Boston Scientific announces court upholds jury verdict against J&J.|
|Next Article:||MatTek's cell-derived tissue model receives United States patent for HIV/AIDS research.|